Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by splenomegaly, systemic symptoms, and anemia, the latter being strongly associated with poor survival and reduced quality of life. Current Janus kinase (JAK) inhibitors improve symptoms and spleen size but often exacerbate anemia, leaving a sig...
S. A. L. Wever, M. Hoogendoorn, S. K. Klein et al.· Critical reviews in oncology...· 0 citations
Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing, and Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies.
Zaid N. Al Shirity, P. Mian, A. Dontje et al.· Clinical Pharmacokinetics· 0 citations
Assessing the coexistence of normal and pathologic MCs is a widely available, fast, and sensitive diagnostic and prognostic tool and may also be used in SM disease follow-up and treatment monitoring.
Abdulrazzaq Alheraky, K. Meijer, Marije T. Nijk et al.· Cytometry. Part B, Clinical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.